drugset / Trial / NCT01116128
Dasatinib in Combination With Melphalan and Prednisone to Treat Relapsed and Refractory Multiple Myeloma Patients
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Clinically demonstrated efficacy of Melphalan and Prednisone in MM subjects as well as the confirmed inhibitory effect of dasatinib on several tyrosine kinase receptors and pathways implicated in the pathophysiology of MM. Additionally, as a SRC inhibitor, dasatinib plays an important role on bone metabolism through inhibition of osteoclast-mediated bone resorption in vitro. Dasatinib could, thus, be beneficial on bone density of patients on study, through blockage of osteolysis and control of bone lesions.
Timeline
- Start
- 2008-02
- Primary completion
- 2011-05
- Completion
- 2011-05
Outcome
Outcome not reported
Stopped (Enrollment): “difficulty in enrolling patients”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Melphalan | Small molecule | 0.18 mg/kg | — |
| Subject | Prednisone | Other / unclassified | 1.5 mg/kg | — |
| Subject | dasatinib anhydrous | Small molecule | 100 mg | — |